The price of Schering's shares barely budged that week, however, and trading volume was steady.
For almost five years, Schering-Plough has been waiting for its labs to produce a new hit.
Moliterno, chief of cardiology at the University of Kentucky, who conducted Schering's 1, 000-patient clinical trial.
Schering-Plough, which has long dominated the interferon market, sells the very similar polymer-coated interferon called Peg-Intron.
Schering-Plough 's earnings in 2003 may be little more than half what they were in 2002.
Schering-Plough is working on the control problems with the FDA and should have them resolved shortly.
The negative result is likely to result in further scrutiny of Merck and Schering.
Schering posted quarterly earnings per share of 12 cents, 2 cents more than analyst forecasts.
With Zetia, Schering's laboratories have given Kogan what could be a very important medicine.
The threat of generic competition against Schering-Plough's similar prescription pill, Clarinex, took care of that.
The e-mail was forwarded to Enrico Veltri, the Schering-Plough executive helping run the trial.
"We pull together panels and seek expert advice on an ongoing basis, " says Schering-Plough spokesman Davies.
That deal failed, as another German drug firm, Bayer of Leverkeusen, merged with Schering.
One scenario has Hassan selling Schering-Plough to Merck and assuming the top job postmerger.
The Kenilworth, New Jersey-based Schering-Plough has lost two-thirds of its market value since 2000.
The most impressive experimental drug Schering is developing is an anti-clot agent to prevent heart attacks.
That was a dead end, but Schering was desperately seeking a thrombin receptor drug.
Veltri also had been running the development of another Schering-invented drug, the thrombin receptor antagonist vorapaxar.
At the time, the marketing of the drugs was split between Schering-Plough and Merck.
Merck and Schering have stood resolutely behind the safety and effectiveness of Zetia and Vytorin.
Deutsche Bank does investment banking and owns 1% or more of both Merck and Schering-Plough.
But until and unless the manufacturing problems are resolved, investors should be very wary of Schering-Plough.
The immediate drain on Schering's earnings will be the disappearance of Claritin as a best-selling drug.
Invented by scientists in Schering-Plough's laboratories, it prevents cholesterol from being absorbed in the digestive system.
The news came after a two-day stock slide that left Schering shares at 1996 prices.
In October, Schering lowered its estimates for 2003, but the news seemed to leak out early.
And Merck and Schering-Plough scrapped plans to do a Vytorin imaging trial with him.
By May 29th only 18.5% of Schering shares had been tendered into the takeover.
ECONOMIST: Two historic German drugs firms scrap for control of a third
The current gold standard of treatment is Schering-Plough's Rebetron, on the market for three years.
In addition, five DAX companies--Commerzbank, Infineon, Metro, Schering and Thyssen-Krupp--already comply with all governance coderecommendations.
应用推荐